CVE:EPI ESSA Pharma (EPI) Stock Price, News & Analysis → [BUY ALERT] Our #1 A.I. Stock for March (From Behind the Markets) (Ad) Free EPI Stock Alerts C$8.20 +0.55 (+7.19%) (As of 10/30/2020) Add Compare Share Share Today's RangeC$7.33▼C$8.2050-Day RangeC$8.20▼C$8.2052-Week RangeC$4.00▼C$11.34Volume1,430 shsAverage Volume4,834 shsMarket CapitalizationC$237.87 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get ESSA Pharma alerts: Email Address Ad Behind the Markets[BUY ALERT] Our #1 A.I. Stock for MarchIt's the one AI stock nobody is talking about. Cathy Wood just bought 11 million shares of it.Get the name of the stock here - before it takes off >>> About ESSA PharmaESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer. It develops EPI-7386, an oral candidate that is in a Phase I clinical study for the treatment of patients with metastatic castration-resistant prostate cancer. The company was founded in 2009 and is headquartered in Vancouver, Canada.Read More EPI Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart EPI Stock News HeadlinesNo headlines for this company have been tracked by MarketBeat.com Receive EPI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ESSA Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeCVE SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A Current SymbolCVE:EPI CUSIPN/A CIKN/A Webessapharmaceuticals.com Phone+1-778-3310962FaxN/AEmployees25Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.04 Current Ratio37.29 Quick Ratio36.72 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowC$2.21 per share Price / Cash Flow3.72 Book ValueC$2.21 per share Price / Book3.72Miscellaneous Outstanding Shares29,009,000Free FloatN/AMarket CapC$237.87 million OptionableNot Optionable BetaN/A Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesDr. David Ross Parkinson (Age 71)Pres, CEO & Director Comp: $626.81kMr. David S. Wood C.M.A. (Age 64)CPA, M.B.A., MBA, CPA, CMA, Chief Financial Officer Comp: $311.52kMr. Peter A. Virsik M.B.A. (Age 50)M.S., Exec. VP & COO Comp: $544.66kDr. Alessandra CesanoChief Medical OfficerChandtip ChandhasinExec.Erica OsbourneExec.Erin RudsinskiExec.Leah DimascioExec.Loleta HarrisExec.Neil ThaparExec.More ExecutivesKey CompetitorsCipher PharmaceuticalsTSE:CPHICC LabsCVE:ICCSupreme CannabisTSE:FIRERIV CapitalTSE:RIVLeaf MobileTSE:LEAFView All Competitors EPI Stock Analysis - Frequently Asked Questions How have EPI shares performed in 2024? ESSA Pharma's stock was trading at C$8.20 at the beginning of the year. Since then, EPI shares have increased by 0.0% and is now trading at C$8.20. View the best growth stocks for 2024 here. Is ESSA Pharma a good dividend stock? ESSA Pharma (CVE:EPI) pays an annual dividend of C$0.22 per share and currently has a dividend yield of 0.00%. What other stocks do shareholders of ESSA Pharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other ESSA Pharma investors own include Aurora Cannabis (ACB), Air Canada (AC), Arbutus Biopharma (ABUS), AB Science (ABSCF), AB International Group (ABQQ), AB Dynamics (ABDP), Advantage Energy (AAV), AA (AATDF), AAON (AAON) and AAC Technologies (AACAY). How do I buy shares of ESSA Pharma? Shares of EPI stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.Compare Top Brokerages Here. This page (CVE:EPI) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyBREAKING: New AI Breakthrough Could Change Healthcare ForeverBehind the Markets“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisorySHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceBuy this small stock before coming AI Tidal WaveChaikin Analytics Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ESSA Pharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.